Information Provided By:
Fly News Breaks for March 20, 2019
NVRO
Mar 20, 2019 | 07:58 EDT
As previously reported, BofA/Merrill upgraded Nevro to Buy from Neutral and raised its price target to $70 from $50. Analyst Bob Hopkins said new CEO Keith Grossman is the "best SMid cap commercial turn-around CEO in MedTech." The analyst said Mr. Grossman's sill set is well suited to address Nevro's current challenges combined with a healthy addressable market and full pipeline.
News For NVRO From the Last 2 Days
There are no results for your query NVRO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.